Revised Japan Prices Include Big Cuts For Gilead HCV Drugs
This article was originally published in PharmAsia News
With policy surrounding the regular drug price revision in Japan next month finalized and a list of new tariff prices just released, it has become clear that Gilead is facing sizeable reimbursement reductions for its two big-selling hepatitis C drugs in the country.
You may also be interested in...
Against the protests of the innovative pharma industry, Japan is pushing ahead with an overhaul of its drug reimbursement pricing system that will include a shift to annual price revisions.
Merck’s Keytruda could see its launch price set lower too after Opdivo’s rapidly rising use in lung cancer triggers maximum statutory price cut.
Sharply rising medical spending in Japan, driven in part by expensive new drugs, is now attracting attention at the highest political levels, with a key prime ministerial council set to debate potential cost-cutting measures.